my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
At Elevian, we are developing new medicines that promote recovery and regeneration. Our lead program is a recombinant protein for the treatment of stroke in the days following the event, for which there are currently no viable treatments. By promoting regeneration, Elevian’s medicines have the potential to treat and prevent many aging-associated diseases.
Elevian is developing a recombinant protein called rGDF11 that has been demonstrated to facilitate recovery of motor function in well-established animal models of ischemic and hemorrhagic stroke. rGDF11 promotes neovascularization (new blood vessel formation), stimulates neurogenesis (new neuron formation), and reduces inflammation. The effects of rGDF11 seem to be independent of the type of injury (clots vs. bleeds). The beneficial effects of rGDF11 are not limited to stroke. rGDF11 has been demonstrated to promote recovery and regeneration in several preclinical models of aging-related diseases, including cardiovascular, neurological, metabolic, pulmonary, renal, inflammatory, and skeletal muscle dysfunction.
Merck announced that Elevian has been selected as the North American winner of its 2021 Advance Biotech Grant Program. The early-stage biotechnology company, which is based in Allston, Massachusetts, USA, was selected for its innovative recombinant protein, which has the potential to accele ... > more
Merck Announces Elevian as Winner of its North American Advance Biotech Grant
Merck announced that Elevian has been selected as the North American winner of its 2021 Advance Biotech Grant Program. The early-stage biotechnology company, which is based in Allston, Massachusetts, USA, was selected for its innovative recombinant protein, which has the potential to accele ... more
